OPS
BBIO icon

Orion Portfolio Solutions’s BridgeBio Pharma BBIO Stock Holding History

Orion Portfolio Solutions’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,192
Closed -$240K – 1686
2023
Q4 		$240K Buy
+6,192
New +$186K ﹤0.01% 1499

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Orion Portfolio Solutions's BBIO Position: Q1 2024 in Review

Orion Portfolio Solutions sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 6,192 shares — an estimated $240K sold.

Orion Portfolio Solutions first reported a position in BBIO in Q4 2023 and held it in 1 quarter. The position peaked at $240K in Q4 2023. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

  • Orion Portfolio Solutions reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
  • Orion Portfolio Solutions sold 6,192 BridgeBio Pharma shares in Q1 2024, an estimated $240K.
  • Orion Portfolio Solutions first reported a position in BridgeBio Pharma in Q4 2023 and held it in 1 quarter.
  • Orion Portfolio Solutions's BridgeBio Pharma position peaked at $240K in Q4 2023.
  • 244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Orion Portfolio Solutions's 13F filing for Q1 2024, filed 9 May 2024.